Publication: 3431

Publication: 3431

Alliance/CALGB 80802 impact of hepatitis C (HCV) on doxorubicin (D) + sorafenib (S) vs. s in patients (pts) advanced HCC (aHCC)

URL

Google Scholar

Citation:: J Clin Oncol vol 39 (3_suppl) 325

Meeting Instance:: ASCO GI 2021
Year:: 2021
Type:: Abstract
Sub type:: Poster Discussion
Funding:: NCTN
Endpoint:: Secondary-not-in-original
Analysis:: Primary
Data Sharing:: No-Data-Sharing
Status:: Presented/Published
Citation Status:: epub

Note:

Methodological:: No
Biospecimen:: Yes
SDC:: No

Parents:: None
Children:: 3764

Program:: OGC
Primary Committee:: GI
Sec. Committees:

Pharmas:: Bayer
Grants:: U10CA180821, U10CA180882, U24CA196171;

Corr. Author:
Authors:: Imane El Dika Susan M. Geyer Andrew Nixon Federico Innocenti Qian Shi Sawyer B. Jacobson Amin Yaqubie Juan Lopez Binhui Huang Yi-Wei Tang Yujia Wen Lawrence H. Schwartz Monica M. Bertagnolli Jeffrey Meyerhardt Eileen M. O'Reilly Alan P. Venook Ghassan K. Abou-Alfa

Networks:: CA824, LAPS-MA036, LAPS-NC007, LAPS-NC010, LAPS-NY016

Study: CALGB-80802
Multiple Studies, or Legacy Studies in Alliance Study:
Phases:: 3

Keywords: